Deqi Pharmaceutical's Selinexor New Drug Listing Application Receives Priority Review by NMPA

On February 24, Deqi Pharmaceuticals announced that the National Medical Products Administration (NMPA) has awarded the world’s first Selective Inhibitor of Nuclear Export ("SINE") ATG-010 (selinexor, XPOVIO®) New drug application (NDA) priority review qualification for the treatment of patients with refractory and relapsed multiple myeloma (rrMM).

As the world's first approved SINE compound, ATG-010 can cause nuclear storage and activation of tumor suppressor proteins and other growth regulatory proteins, and down-regulate the levels of multiple oncoproteins in the cytoplasm, and induce tumor cells in vitro and in vivo Apoptosis, while normal cells are not affected.

"ATG-010 provides new ideas for the treatment of patients with refractory and relapsed multiple myeloma.

In order to accelerate the registration and research of drugs with important clinical value, the National Medical Products Administration implemented the "Working Procedures for Priority Review and Approval of Drug Marketing Authorization (Trial)" on July 7, 2020.

About ATG-010 (selinexor, XPOVIO®)

ATG-010 (selinexor, XPOVIO®) is the first and only oral selective nuclear export inhibitor (SINE) compound of its kind, developed by Karyopharm Therapeutics Inc.

In July 2019, the U.

Note: The original text has been deleted